Novyra Pharmachem Q2 FY27 Results: Net Loss Rs. 3.32 Lakhs
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 02 Nov 2026, 05:51 PM IST · BSE ID: 509bf689-04db-4540-8af1-7486ead1d8a0
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved its latest financial results, showing a net loss of Rs. 3.32 Lakhs for the quarter.
🤖 AI Summary
- Board of Directors approved Q2 FY27 unaudited financial results on November 02, 2026.
- Company reported a net loss of Rs. 3.32 Lakhs for the quarter ended September 30, 2026.
- Total Revenue from Operations reached Rs. 426.78 Lakhs for Q2 FY27.
- The unaudited financial results were subject to a limited review by statutory auditors.
- Total Current Assets as of September 30, 2026, stood at Rs. 203.94 Lakhs.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Net Profit/(Loss) for the Period (Q2 FY27)
(3.32) Lakhs
Not comparable — limited prior period data.
Total Revenue from Operations (Q2 FY27)
426.78 Lakhs
Not comparable — limited prior period data.
Total Equity (as of September 30, 2026)
56.89 Lakhs
Total Current Liabilities (as of September 30, 2026)
264.81 Lakhs
Cash and cash equivalents (as of September 30, 2026)
23.28 Lakhs
🏢 How This Affects the Company
Novyra Pharmachem's business operations were reviewed by the Board, confirming ongoing activities across its Pharma, Real Estate, and Tea Estate segments.
The company recorded a Net Loss for the Period of Rs. 3.32 Lakhs in Q2 FY27. Total Current Liabilities increased to Rs. 264.81 Lakhs as of September 30, 2026, from Rs. 86.67 Lakhs as of March 31, 2026.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, as reported by the Net Loss of Rs. 3.32 Lakhs in Q2 FY27 and the decline in Total Equity to Rs. 56.89 Lakhs.
🔍
Management Signal
The Board's approval of results and review of business indicates management's adherence to regulatory reporting and ongoing oversight of operations despite a quarterly loss.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results — assess profitability trends and revenue growth.
Any further business updates regarding segment-wise performance.
Review of Half Year Ended September 30, 2027 figures for comparative analysis.
MEDIUM RISK
The company reported a net loss for the quarter and experienced a decrease in total equity, indicating financial performance challenges.
💡 Investor Takeaway
Novyra Pharmachem Ltd reported a Net Loss of Rs. 3.32 Lakhs for Q2 FY27, a decline from a Net Profit of Rs. 0.10 Lakhs in Q2 FY26. Total Revenue from Operations grew to Rs. 426.78 Lakhs for Q2 FY27 from Rs. 3.31 Lakhs in Q2 FY26. Total Equity decreased to Rs. 56.89 Lakhs.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations increased to Rs. 426.78 Lakhs in Q2 FY27 compared to Rs. 3.31 Lakhs in Q2 FY26.
- Cash and cash equivalents increased to Rs. 23.28 Lakhs as of September 30, 2026, from Rs. 17.72 Lakhs as of March 31, 2026.
⚠️ Concerns
- The company reported a Net Loss of Rs. 3.32 Lakhs for Q2 FY27, compared to a Net Profit of Rs. 0.10 Lakhs in Q2 FY26.
- Total Equity decreased to Rs. 56.89 Lakhs as of September 30, 2026, from Rs. 59.21 Lakhs as of March 31, 2026.
📅 Company Track Record
Novyra Pharmachem Ltd (formerly Bansisons Tea Industries Ltd) had a Board meeting announced on October 23, 2026, to approve these Q2 FY27 Unaudited Financial Results. The company's prior fiscal year (FY26) showed a Net Loss of (537.38) Lakhs.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Novyra Pharmachem Ltd's net profit/loss for Q2 FY27?
Novyra Pharmachem Ltd reported a Net Loss of Rs. 3.32 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was the total revenue from operations for Novyra Pharmachem in Q2 FY27?
The Total Revenue from Operations for Novyra Pharmachem Ltd in Q2 FY27 was Rs. 426.78 Lakhs.
What is Novyra Pharmachem's Total Equity as of September 30, 2026?
As of September 30, 2026, Novyra Pharmachem Ltd's Total Equity stood at Rs. 56.89 Lakhs.
How much were Novyra Pharmachem's Total Current Liabilities in Q2 FY27?
Novyra Pharmachem Ltd reported Total Current Liabilities of Rs. 264.81 Lakhs as of September 30, 2026.
Questions based on this BSE filing only. For information purposes.